Sangamo (SGMO) research chief sells 69,827 shares around $0.25

Q: At what price did Gregory D. Davis sell SGMO shares in this Form 4 filing?

Gregory D. Davis sold his SGMO common shares at a weighted-average price of $0.2534 per share. The filing notes multiple trades with prices ranging from $0.2533 to $0.2568 , and offers to provide detailed price breakdowns upon request.

Q: How many Sangamo Therapeutics (SGMO) shares did Gregory D. Davis sell and how many does he still own?

Gregory D. Davis sold 69,827 shares of Sangamo Therapeutics common stock in this transaction. Following the sale, he directly owns 115,284 shares of SGMO common stock, as reported in the Form 4 filing’s post-transaction holdings.

Q: What type of transaction is disclosed for SGMO executive Gregory D. Davis?

The filing describes the transaction as an open-market sale of Sangamo Therapeutics common stock by executive Gregory D. Davis. It is coded as a “S” transaction , meaning a sale in the open market or a private transaction under SEC reporting rules.

Q: Does the Sangamo Therapeutics (SGMO) Form 4 mention a weighted-average price for the Davis sale?

Yes. The Form 4 explains that the reported price is a weighted-average of multiple trades. Shares were sold at prices between $0.2533 and $0.2568 , with the weighted-average sale price disclosed as $0.2534 per share in the filing.

Q: Who is the insider involved in the latest SGMO Form 4 and what is his role?

The insider is Gregory D. Davis , who serves as Head of Research & Technology at Sangamo Therapeutics. The Form 4 attributes the open-market sale of common stock directly to him, reflecting his executive role and direct ownership position in the company.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, sold common stock in an open-market transaction. On April 22, 2026, he sold 69,827 shares of Sangamo Therapeutics common stock at a weighted-average price of $0.2534 per share, with individual trades ranging from $0.2533 to $0.2568. After this sale, Davis directly holds 115,284 shares of the company’s common stock.

Insider Trade Summary

Net Seller: 69,827 shares ($17,694)

Net Sell 1 txn

Insider Davis Gregory D

Role Head of Research & Technology

Sold 69,827 shs ($18K)

Type	Security	Shares	Price	Value
Sale	Common Stock	69,827	$0.2534	$18K

Holdings After Transaction: Common Stock — 115,284 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 69,827 shares Weighted-average sale price: $0.2534 per share Post-sale holdings: 115,284 shares +2 more

5 metrics

Shares sold 69,827 shares Open-market sale of common stock on April 22, 2026

Weighted-average sale price $0.2534 per share Average price for multiple trades in the reported sale

Post-sale holdings 115,284 shares Common stock directly owned after the transaction

Price range of trades $0.2533–$0.2568 per share Range of individual sale prices within the transaction

Net shares sold 69,827 shares Net change in position from this Form 4, all sales

Key Terms

open-market sale, weighted-average price, Common Stock, Form 4

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted-average price financial

"The price reported is a weighted-average price."

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/23/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Gregory D

(Last)

(First)

(Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BLVD.

(Street)

RICHMOND

CALIFORNIA

94804

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Head of Research & Technology

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/22/2026		S		69,827	D	$0.2534⁽¹⁾	115,284	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2568, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	/s/ Scott Willoughby, Attorney-in-Fact	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sangamo Therapeutics (SGMO) report for Gregory D. Davis?

Sangamo Therapeutics reported that executive Gregory D. Davis completed an open-market sale of 69,827 shares of common stock. The transaction occurred on April 22, 2026 and was executed at a weighted-average price of $0.2534 per share.

At what price did Gregory D. Davis sell SGMO shares in this Form 4 filing?

Gregory D. Davis sold his SGMO common shares at a weighted-average price of $0.2534 per share. The filing notes multiple trades with prices ranging from $0.2533 to $0.2568, and offers to provide detailed price breakdowns upon request.

How many Sangamo Therapeutics (SGMO) shares did Gregory D. Davis sell and how many does he still own?

Gregory D. Davis sold 69,827 shares of Sangamo Therapeutics common stock in this transaction. Following the sale, he directly owns 115,284 shares of SGMO common stock, as reported in the Form 4 filing’s post-transaction holdings.

What type of transaction is disclosed for SGMO executive Gregory D. Davis?

The filing describes the transaction as an open-market sale of Sangamo Therapeutics common stock by executive Gregory D. Davis. It is coded as a “S” transaction, meaning a sale in the open market or a private transaction under SEC reporting rules.

Does the Sangamo Therapeutics (SGMO) Form 4 mention a weighted-average price for the Davis sale?

Yes. The Form 4 explains that the reported price is a weighted-average of multiple trades. Shares were sold at prices between $0.2533 and $0.2568, with the weighted-average sale price disclosed as $0.2534 per share in the filing.

Who is the insider involved in the latest SGMO Form 4 and what is his role?

The insider is Gregory D. Davis, who serves as Head of Research & Technology at Sangamo Therapeutics. The Form 4 attributes the open-market sale of common stock directly to him, reflecting his executive role and direct ownership position in the company.